MedTrace Logo

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 534

Last updated 2023-04-13

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

Conditions

Interventions

DRUG

Dexpramipexole

dexpramipexole twice daily oral dosing for up to 12 weeks

DRUG

Placebo

placebo twice daily oral dosing for up to 12 weeks

Sponsors & Collaborators

  • Knopp Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2020-12-03
Completion
2021-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04046939 on ClinicalTrials.gov